Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd has completed the validation of its ColoSTAT® assay and submitted a request to include it in the ISO15189 accreditation scope, paving the way for its commercialization. The ColoSTAT® test, which has shown high sensitivity and negative predictive value for colorectal cancer detection, offers a non-invasive alternative to stool-based tests and could significantly impact early cancer detection and patient management.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden through innovative diagnostic solutions. Rhythm collaborates with global partners to commercialize and distribute its products.
Average Trading Volume: 730,937
Technical Sentiment Signal: Buy
Current Market Cap: A$26.76M
Learn more about RHY stock on TipRanks’ Stock Analysis page.